
Urinary Tract Infection Market
Urinary Tract Infection Market Forecasts to 2030 - Global Analysis By Product (Azoles and Amphotericin B, Cephalosporin, Nitrofurans, Penicillin and Combinations, Quinolones and Other Products), Treatment Type, Test Type, Indication, Distribution Channel, End User and By Geography

Years Covered |
2021-2030 |
Estimated Year Value (2023) |
US $6.60 BN |
Projected Year Value (2030) |
US $11.07 BN |
CAGR (2023 - 2030) |
7.67% |
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
Largest Market |
Asia Pacific |
Highest Growing Market |
Europe |
According to Stratistics MRC, the Global Urinary Tract Infection Market is accounted for $6.60 billion in 2023 and is expected to reach $11.07 billion by 2030 growing at a CAGR of 7.67% during the forecast period. Urinary Tract Infections is a test of urine to detect and manage a wide range of disorders, such as urinary tract infections, kidney disease and diabetes. UTIs, caused primarily by bacteria entering the urethra and multiplying in the urinary tract, are common medical conditions. It serves the healthcare sector by providing diagnostic tools, antibiotics, and therapeutics tailored for UTI management.
According to the American Academy of Family Physicians (AAFP), in March 2020, by Leonardo Ferreira, kidney stones were a common ailment, with an annual incidence of eight instances per 1,000 persons. As per the same source, around 13% of men and 7% of women may develop a kidney stone during their lifetime, and the total incidence of urinary retention in the US is 4.5 to 6.8 per 1,000 men per year.
Market Dynamics:
Driver:
Increasing prevalence of urinary tract infections
The increasing prevalence of urinary tract infections (UTIs), especially in women, the elderly, and people with weakened immune systems, is driving up demand for diagnostic and treatment options. The aging population, increased knowledge of UTIs, and a growing emphasis on early detection and timely treatment are some of the factors driving the UTI market's growth. Furthermore, the need for novel diagnostics, antibiotics, and preventive measures is highlighted by this market driver, which encourages investment and research in the creation of fresh goods and remedies for UTIs.
Restraint:
Rising instances of antibiotic resistance
Effective treatment of urinary tract infections is becoming more difficult due to the emergence of resistant bacterial strains caused by the overuse and misuse of antibiotics. The need for new therapeutic solutions arises from the fact that this resistance limits the effectiveness of current antibiotics and complicates standard treatment regimens. In order to combat antibiotic resistance in UTI management, research and development efforts must be concentrated in order to find new medications and alternative treatment modalities.
Opportunity:
Adoption of novel diagnostic technologies
Point-of-care diagnostics and rapid molecular testing are instances of advanced diagnostic tools that can help identify UTIs more quickly and accurately. This helps to effectively use antibiotics, addressing the growing concern of antibiotic resistance, and improves patient care by enabling timely treatment. Businesses that invest in cutting-edge UTI diagnostic solutions will profit from the growing need for accurate and efficient diagnostic techniques, which will enhance overall healthcare outcomes and lessen the financial burden of UTI treatment.
Threat:
Lack of awareness
UTIs, common bacterial infections affecting the urinary system, often go undetected due to insufficient public knowledge about their causes, symptoms, and preventive measures. This dearth of awareness hampers early diagnosis and timely medical intervention, leading to complications and increased healthcare costs. However, misconceptions and inadequate information about hygiene practices contribute to the prevalence of UTIs. The lack of awareness not only affects individual health outcomes but also burdens healthcare systems.
Covid-19 Impact:
The overwhelming focus on managing and containing the virus has diverted healthcare resources, attention, and funding away from other medical conditions, including UTIs. Lockdowns, restricted healthcare access, and patient concerns about visiting medical facilities have led to delayed diagnoses and treatments, exacerbating the severity of UTIs. Moreover, the increased use of antibiotics to treat Covid-19-related bacterial infections has contributed to antibiotic resistance, potentially limiting the effectiveness of standard UTI treatments. Supply chain disruptions have also affected the availability of UTI medications and diagnostics.
The antibiotics segment is expected to be the largest during the forecast period
The antibiotics segment expected to have largest share over the anticipated period. A wide variety of medications are used to treat bacterial infections of the urinary tract in the Urinary Tract Infection market's antibiotics segment. Beta-lactam antibiotics, like amoxicillin, and fluoroquinolones, like ciprofloxacin, are frequently prescribed antibiotics for urinary tract infections. Additionally, the goals of ongoing research and development are to reduce side effects, minimize resistance, and improve the effectiveness of these antibiotics.
The clinical laboratories segment is expected to have the highest CAGR during the forecast period
Clinical laboratories segment in the urinary tract infection market is expected to have profitable growth. Clinical laboratories are pivotal in the identification and confirmation of UTIs through the analysis of urine samples, which includes assessing bacterial presence and determining antibiotic susceptibility. These laboratories utilize advanced technologies and testing methods to ensure accurate and timely results, facilitating prompt medical intervention. Moreover, the adoption of automation and molecular diagnostic techniques within these laboratories enhances the efficiency and precision of UTI diagnostics.
Region with largest share:
The Asia-Pacific Urinary Tract Infection market is expanding substantially due to the need for diagnostic and treatment solutions is being driven by rising healthcare costs, better healthcare infrastructure, and increased awareness of UTIs. The increased frequency of UTIs is also attributed to a changing lifestyle and an aging population. Additionally, favourable government initiatives and the growth of pharmaceutical and healthcare companies are driving the regional growth.
Region with highest CAGR:
The market for urinary tract infections is expanding substantially in Europe due to a growing geriatric population and rising public awareness. The market is growing due to risk factors like diabetes and urine incontinence are becoming more common, which is also driving growth in Europe. Additionally, government campaigns to raise awareness of urinary health issues and encourage preventative measures have been crucial in driving market growth in the European Union.
Key players in the market
Some of the key players in Urinary Tract Infection market include Abbott Laboratories , Acon Laboratories, Inc., Allergan Plc, Arkray, Inc., Astrazeneca Plc, Bayer Ag , Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Elektronika Kft., F. Hoffmann-La Roche Ltd, Glaxosmithkline Plc, Johnson & Johnson, Merck & Co. Inc, Mindray Medical International Limited, Novartis Ag, Pfizer Inc, Roche Diagnostics, Sanofi S.A., Siemens Healthcare, Sysmex Corporation and Urit Medical Electronic Group Co., Ltd.
Key Developments:
In December 2023, Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies. The Agreement is based on a basic agreement on business collaboration in the field of immunoassay. Under the terms of the Agreement, Fujirebio and Sysmex will mutually supply a wide range of reagent materials owned by each company, mainly antigens and antibodies, which are the main raw materials of immunoassay reagents.
In December 2023, AstraZeneca Pharma India has entered into a Memorandum of Understanding (MoU) with Roche Diagnostics India to enhance diagnostics for breast cancer patients, particularly focusing on refining HER2 diagnostics with the latest advancements. This strategic alliance aligns with AstraZeneca's commitment to advancing patient-centric healthcare solutions and Roche Diagnostics' dedication to pioneering diagnostic innovation.
Products Covered:
• Azoles and Amphotericin B
• Cephalosporin
• Nitrofurans
• Penicillin and Combinations
• Quinolones
• Other Products
Treatment Types Covered:
• Antibiotics
• Analgesics
• Antispasmodics
• Other Treatment Types
Test Types Covered:
• Microscopic Urinary Tract Infections
• Biochemical Urinary Tract Infections
• Flow Cytometric Urinary Tract Infections
• Other Test Types
Indications Covered:
• Complicated Urinary Tract Infection
• Neurogenic Bladder Infections
• Recurring Complicated Urinary Tract Infection
• Uncomplicated Urinary Tract Infection
• Other Indications
Distribution Channels Covered:
• Drug Stores
• Gynaecology and Urology Clinics
• Retail Pharmacies
• Other Distribution Channels
End Users Covered:
• Hospitals
• Clinical Laboratories
• Home Healthcare
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Urinary Tract Infection Market, By Product
5.1 Introduction
5.2 Azoles and Amphotericin B
5.3 Cephalosporin
5.4 Nitrofurans
5.5 Penicillin and Combinations
5.6 Quinolones
5.7 Other Products
6 Global Urinary Tract Infection Market, By Treatment Type
6.1 Introduction
6.2 Antibiotics
6.3 Analgesics
6.4 Antispasmodics
6.5 Other Treatment Types
7 Global Urinary Tract Infection Market, By Test Type
7.1 Introduction
7.2 Microscopic Urinary Tract Infections
7.3 Biochemical Urinary Tract Infections
7.4 Flow Cytometric Urinary Tract Infections
7.5 Other Test Types
8 Global Urinary Tract Infection Market, By Indication
8.1 Introduction
8.2 Complicated Urinary Tract Infection
8.3 Neurogenic Bladder Infections
8.4 Recurring Complicated Urinary Tract Infection
8.5 Uncomplicated Urinary Tract Infection
8.6 Other Indications
9 Global Urinary Tract Infection Market, By Distribution Channel
9.1 Introduction
9.2 Drug Stores
9.3 Gynaecology and Urology Clinics
9.4 Retail Pharmacies
9.5 Other Distribution Channels
10 Global Urinary Tract Infection Market, By End User
10.1 Introduction
10.2 Hospitals
10.3 Clinical Laboratories
10.4 Home Healthcare
10.5 Other End Users
11 Global Urinary Tract Infection Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Abbott Laboratories
13.2 Acon Laboratories, Inc.
13.3 Allergan Plc
13.4 Arkray, Inc.
13.5 Astrazeneca Plc
13.6 Bayer Ag
13.7 Beckman Coulter, Inc.
13.8 Bio-Rad Laboratories, Inc.
13.9 Elektronika Kft.
13.10 F. Hoffmann-La Roche Ltd
13.11 Glaxosmithkline Plc
13.12 Johnson & Johnson
13.13 Merck & Co. Inc
13.14 Mindray Medical International Limited
13.15 Novartis Ag
13.16 Pfizer Inc
13.17 Roche Diagnostics
13.18 Sanofi S.A.
13.19 Siemens Healthcare
13.20 Sysmex Corporation
13.21 Urit Medical Electronic Group Co., Ltd.
List of Tables
1 Global Urinary Tract Infection Market Outlook, By Region (2021-2030) ($MN)
2 Global Urinary Tract Infection Market Outlook, By Product (2021-2030) ($MN)
3 Global Urinary Tract Infection Market Outlook, By Azoles and Amphotericin B (2021-2030) ($MN)
4 Global Urinary Tract Infection Market Outlook, By Cephalosporin (2021-2030) ($MN)
5 Global Urinary Tract Infection Market Outlook, By Nitrofurans (2021-2030) ($MN)
6 Global Urinary Tract Infection Market Outlook, By Penicillin and Combinations (2021-2030) ($MN)
7 Global Urinary Tract Infection Market Outlook, By Quinolones (2021-2030) ($MN)
8 Global Urinary Tract Infection Market Outlook, By Other Products (2021-2030) ($MN)
9 Global Urinary Tract Infection Market Outlook, By Treatment Type (2021-2030) ($MN)
10 Global Urinary Tract Infection Market Outlook, By Antibiotics (2021-2030) ($MN)
11 Global Urinary Tract Infection Market Outlook, By Analgesics (2021-2030) ($MN)
12 Global Urinary Tract Infection Market Outlook, By Antispasmodics (2021-2030) ($MN)
13 Global Urinary Tract Infection Market Outlook, By Other Treatment Types (2021-2030) ($MN)
14 Global Urinary Tract Infection Market Outlook, By Test Type (2021-2030) ($MN)
15 Global Urinary Tract Infection Market Outlook, By Microscopic Urinary Tract Infections (2021-2030) ($MN)
16 Global Urinary Tract Infection Market Outlook, By Biochemical Urinary Tract Infections (2021-2030) ($MN)
17 Global Urinary Tract Infection Market Outlook, By Flow Cytometric Urinary Tract Infections (2021-2030) ($MN)
18 Global Urinary Tract Infection Market Outlook, By Other Test Types (2021-2030) ($MN)
19 Global Urinary Tract Infection Market Outlook, By Indication (2021-2030) ($MN)
20 Global Urinary Tract Infection Market Outlook, By Complicated Urinary Tract Infection (2021-2030) ($MN)
21 Global Urinary Tract Infection Market Outlook, By Neurogenic Bladder Infections (2021-2030) ($MN)
22 Global Urinary Tract Infection Market Outlook, By Recurring Complicated Urinary Tract Infection (2021-2030) ($MN)
23 Global Urinary Tract Infection Market Outlook, By Uncomplicated Urinary Tract Infection (2021-2030) ($MN)
24 Global Urinary Tract Infection Market Outlook, By Other Indications (2021-2030) ($MN)
25 Global Urinary Tract Infection Market Outlook, By Distribution Channel (2021-2030) ($MN)
26 Global Urinary Tract Infection Market Outlook, By Drug Stores (2021-2030) ($MN)
27 Global Urinary Tract Infection Market Outlook, By Gynaecology and Urology Clinics (2021-2030) ($MN)
28 Global Urinary Tract Infection Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
29 Global Urinary Tract Infection Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
30 Global Urinary Tract Infection Market Outlook, By End User (2021-2030) ($MN)
31 Global Urinary Tract Infection Market Outlook, By Hospitals (2021-2030) ($MN)
32 Global Urinary Tract Infection Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
33 Global Urinary Tract Infection Market Outlook, By Home Healthcare (2021-2030) ($MN)
34 Global Urinary Tract Infection Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY

We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?

Assured Quality
Best in class reports with high standard of research integrity

24X7 Research Support
Continuous support to ensure the best customer experience.

Free Customization
Adding more values to your product of interest.

Safe & Secure Access
Providing a secured environment for all online transactions.

Trusted by 600+ Brands
Serving the most reputed brands across the world.